Get the Stockscreener App
144.68
16.93%
-29.70
Moderna Inc stock is traded at $144.68, with a volume of 22.14M.
It is down -16.93% in the last 24 hours and up +143.49% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$174.38
Open:
$150.14
24h Volume:
22.14M
Relative Volume:
2.36
Market Cap:
$57.59B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-17.76
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+127.57%
1M Performance:
+143.49%
6M Performance:
+190.46%
1Y Performance:
+438.68%
1-Day Range:
$140.55
$155.00
1-Week Range:
$60.82
$176.66
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
144.25 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
547.27 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
836.91 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,031.56 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.16 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Morgan Stanley Forecasts Strong Price Appreciation for Moderna (NASDAQ:MRNA) Stock - MarketBeat
Is Cancer the Next Breakthrough for Moderna After COVID-19? - Zacks Investment Research
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets - 24/7 Wall St.
Moderna, Coinbase, Strategy, Walmart, Alibaba, and More Stocks That Explain Today’s Market - Barron's
Moderna (MRNA) Is Up 173.9% After First Successful Phase 3 Individualized mRNA Cancer Therapy TrialWhat's Changed - Yahoo Finance
Why Moderna Stock’s Historic Surge Is a Big Lesson for Markets and 5 Other Things to Know Today - Barron's
Jefferies Adjusts Price Target on Moderna to $150 From $60, Keeps Hold Rating - marketscreener.com
Moderna and Merck revive mRNA hopes with melanoma success - chinadailyasia.com
Moderna shares slide as investors lock in gains after historic cancer vaccine rally - Yahoo Finance
Moderna's Cancer Vaccine Breakthrough: Why AI Healthcare Is Being Repriced - Moomoo
mRNA cancer vaccine succeeds in Phase III trial; Moderna surges 177% in a day, igniting global vaccine sector - finance.biggo.com
Moderna breakthrough: The options lottery tickets that paid out - Seeking Alpha
Will Moderna Wake Up the Health Care Sector? - marketscreener.com
Moderna dips 15% premarket after historic rally - Breakingthenews.net
E Fund Management Co. Ltd. Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
$Moderna (MRNA.US)$ - Moomoo
Edmond DE Rothschild Holding S.A. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Analyst recommendations: Datadog, Merck, Estee Lauder, Moderna, Target… - marketscreener.com
Moderna Inc (Derivatives) price today, MRNA to USD live price, marketcap and chart - CoinMarketCap
Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead (MRNA:NASDAQ) - Seeking Alpha
5,814 Shares in Moderna, Inc. $MRNA Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
After Moderna, How to Spot the Next Short Squeeze on moomoo - Moomoo
Moderna and Merck & Co are the stocks of the day on Wall Street - marketscreener.com
Moderna Doubles on Melanoma Vaccine Win, Treasury Steps In to Cap Long-End Yields - ChartMill
BlackRock Inc. Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Zacks Investment Ideas feature highlights: Moderna and Merck's - Yahoo Finance Singapore
Moderna and Merck shares soar on mRNA cancer vaccine - Axios
Moderna says melanoma vaccine trial shows "landmark moment" in treatment - CBS News
Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines - Financial Times
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - Yahoo Finance
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine WinModerna (NASDAQ:MRNA) - Benzinga
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough - Yahoo Finance
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough - Stocktwits
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Moderna's Most-Traded Call Options Up 54,000,000% on Cancer Vaccine Success | Options Income Daily - Moomoo
Moderna and Merck Revive mRNA Hopes With Melanoma Success - Moomoo
Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer - CBS News
EXPERT REACTION: Moderna announce results of Phase 3 trial of personalized mRNA cancer vaccine - Scimex
US stock futures steady after tech slump; investors focus on Middle East tensions - Yahoo Finance
Cancer vaccine shows promise in late-stage melanoma trial - NewsNation
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna stock surges as melanoma vaccine trial shows "landmark moment" - Yahoo Finance
Wall Street rises as yields ease, Moderna lifts healthcare stocks - Virginia Business
Wall St rises as yields ease, Moderna lifts healthcare stocks - marketscreener.com
Moderna’s skin cancer vaccine shows promise in trial - Semafor
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial - ABC7 Bay Area
Moderna reaches "landmark moment" in Melanoma vaccine trial - CBS News
Moderna says its experimental vaccine prevented melanoma from returning or spreading - CBS News
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):